SecBot SecBot
COURT-RULING ·Filed Jun 4, 2026

AMRN

AMARIN CORP PLCUK
BEARISH
Impact 7/10
Horizonimmediate Processed5mo ago CourtCourt Ruling · courtlistener.com
Court ruling (scotus)
Actionable Insight ▼ Bearish

This ruling is a definitive loss for Amarin, eliminating a key legal tool to prevent generic competition for Vascepa. With induced infringement claims dismissed, Hikma's generic icosapent ethyl can continue to capture market share, pressuring Amarin's revenue. Monitor for potential FDA approvals of additional generics and any impact on Vascepa prescribing patterns. The stock may react negatively on this news.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.80
T+0 close · Jun 4, 2026 · via day close
Latest settled
+1.23%
T+60 · $13.97
Vs SPY
−0.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $13.80entry
  2. T+1 · 6mo ago +0.94%α +3.54% · $13.93
  3. T+5 · 5mo ago +7.97%α +10.52% · $14.90
  4. T+20 · 4mo ago +18.62%α +20.00% · $16.37
  5. T+60 · 3mo ago +1.23%α −0.65% · $13.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a claim for induced infringement against Hikma's generic icosapent ethyl (Vascepa). The decision clarifies that generic manufacturers' compliance with labeling requirements and standard industry practices does not constitute active inducement, effectively dismissing Amarin's lawsuit and removing a key legal barrier to generic competition.

Court Ruling Details

Ruling Date
Jun 4, 2026
Court
Supreme Court of the United States
Court Level
Supreme Court
Judge
Ketanji Brown Jackson
Case Type
patent
Ruling Type
final judgment
Outcome
LOSS: ruling against this company
Precedent Risk
MEDIUM

Key Facts

  • SCOTUS ruled that Amarin's induced infringement complaint failed to plausibly allege active steps encouraging infringement.
  • The Court rejected the Federal Circuit's 'could be read as instruction' standard, requiring affirmative statements or actions.
  • Hikma's skinny label, patient leaflet, website, and press releases were deemed lawful or too vague to support inducement.
  • The ruling allows Hikma to continue marketing generic icosapent ethyl for the severe hypertriglyceridemia (SH) indication without induced infringement liability based on these statements.
  • Amarin's CV-indication method-of-use patents remain valid, but enforcement against skinny-label generics is now significantly constrained.

Financial Impact

No damages awarded; the ruling removes a potential injunctive barrier that could have protected Vascepa's revenue from generic erosion.

revenuemarket_share

Risk Factors

  • Accelerated erosion of Vascepa's market share as generics gain traction without infringement liability.
  • Reduced ability to enforce method-of-use patents against skinny-label generics under the clarified standard.
  • Potential decline in Amarin's revenue and cash flow, impacting its ability to fund operations or pipeline development.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-3axdbk8b-AMRN

Track record

8 reports on AMRN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Oct 28, 202619d ago 8-K Neutral 5/10 No price data
  2. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $12.75 Now $11.31 −11.26% settles Jan 26
  3. Oct 25, 202622d ago Press Release Mixed 6/10 Entry $12.09 Now $11.31 −6.45% settles Jan 22
  4. Aug 28, 202611w ago Press Release Neutral 4/10 Entry $13.97 Now $11.31 −19.04% settles Nov 23
  5. Jun 4, 202623w ago Court Ruling Bearish 7/10 Viewing Entry $13.80 to $13.97 Now $11.31 +18.04% ▼ −1.23% +0.65% vs SPY
  6. Apr 29, 202628w ago 8-K Neutral 4/10 Entry $14.29 to $13.55 Now $11.31 −20.85% ▼ −5.18% −9.29% vs SPY
  7. Mar 16, 202635w ago Press Release Neutral 4/10 Entry $15.42 to $14.20 Now $11.31 −26.65% ▼ −7.91% −18.40% vs SPY
  8. Feb 25, 202637w ago 8-K Bearish 6/10 Entry $14.05 to $14.27 Now $11.31 +19.50% ▼ −1.57% +5.38% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens Wed (10h 1m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Jun 4, 2026